These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24118558)

  • 21. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
    Raschi E; Ceccarini L; De Ponti F; Recanatini M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P; Warner B
    J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].
    Chachin M; Kurachi Y
    Nihon Yakurigaku Zasshi; 2002 Jun; 119(6):345-51. PubMed ID: 12089906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hERG: protein trafficking and potential for therapy and drug side effects.
    Staudacher I; Schweizer PA; Katus HA; Thomas D
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
    Badyra B; Lisowski B; Polak S; Kudolo J; Wiśniowska B
    Folia Med Cracov; 2015; 55(4):5-19. PubMed ID: 26867116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model.
    Yao X; Anderson DL; Ross SA; Lang DG; Desai BZ; Cooper DC; Wheelan P; McIntyre MS; Bergquist ML; MacKenzie KI; Becherer JD; Hashim MA
    Br J Pharmacol; 2008 Aug; 154(7):1446-56. PubMed ID: 18587422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
    Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
    J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
    Furutani K
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
    Bowlby MR; Peri R; Zhang H; Dunlop J
    Curr Drug Metab; 2008 Nov; 9(9):965-70. PubMed ID: 18991593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
    De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
    Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
    Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
    Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H; Livingston FS; Gubler U; Garippa R
    J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac hERG K
    Su S; Sun J; Wang Y; Xu Y
    Handb Exp Pharmacol; 2021; 267():139-166. PubMed ID: 33829343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.